@article{JTD13195,
author = {Marius Ilie and Paul Hofman},
title = {Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what’s next?},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {5},
year = {2017},
keywords = {},
abstract = {Pembrolizumab (Keytruda, Merck & Co) is the first immunotherapy to be approved by FDA in the USA and by EMA in Europe for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 expression (tumor proportion score of 50% or above). Up to now, a chemotherapy doublet has been the standard of care for these patients, except in patients with advanced NSCLC harboring targetable genomic alterations such as EGFR mutations or ALK rearrangements.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/13195}
}